المؤلفون: Kassir N; Genentech, Inc., South San Francisco, CA, USA., McDougall D; Parexel International, Brisbane, Australia., Kuruvilla D; Genentech, Inc., South San Francisco, CA, USA., Kim S; Blueprint Medicines Corporation, Cambridge, MA, USA., Kumar S; Parexel International, Brisbane, Australia., Rahman A; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Ruf T; F. Hoffmann-La Roche, Ltd, Basel, Switzerland., Cheeti S; Genentech, Inc., South San Francisco, CA, USA., Ankrom W; Blueprint Medicines Corporation, Cambridge, MA, USA.

المصدر: Journal of clinical pharmacology [J Clin Pharmacol] 2024 Jun; Vol. 64 (6), pp. 685-696. Date of Electronic Publication: 2024 Feb 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Proto-Oncogene Proteins c-ret*/genetics , Proto-Oncogene Proteins c-ret*/antagonists & inhibitors , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Thyroid Neoplasms*/drug therapy , Thyroid Neoplasms*/genetics, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Dose-Response Relationship, Drug ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/administration & dosage ; Pyrimidinones/therapeutic use ; Pyrimidinones/administration & dosage ; Pyrimidinones/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/administration & dosage ; Progression-Free Survival ; Aged, 80 and over ; Pyrazoles ; Pyridines ; Pyrimidines

المؤلفون: Nassar AH; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Kim SY; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Aredo JV; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California., Feng J; Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, Canada., Shepherd F; Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, Canada., Xu C; Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma., Kaldas D; Department of Internal Medicine, University of South Florida, Tampa, Florida; Department of Clinical Oncology, Cairo University, Cairo, Egypt., Gray JE; Thoracic Oncology Program, Moffitt Cancer Center, Tampa, Florida., Dilling TJ; Thoracic Oncology Program, Moffitt Cancer Center, Tampa, Florida., Neal JW; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California., Wakelee HA; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California., Liu Y; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lin SH; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Abuali T; Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California., Amini A; Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California., Nie Y; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Patil T; Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado., Lobachov A; Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel., Bar J; Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel., Fitzgerald B; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Fujiwara Y; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Marron TU; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Thummalapalli R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Yu H; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York., Owen DH; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Sharp J; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Farid S; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Rocha P; Medical Oncology Department, Hospital del Mar, Barcelona, Spain., Arriola E; Medical Oncology Department, Hospital del Mar, Barcelona, Spain., D'Aiello A; Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Cheng H; Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Whitaker R; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Parikh K; Mayo Clinic, Rochester, Minnesota., Ashara Y; Mayo Clinic, Rochester, Minnesota., Chen L; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Sankar K; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Harris JP; Department of Radiation Oncology, University of California Irvine Medical Center, Orange, California., Nagasaka M; Division of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, California., Ayanambakkam A; Oklahoma University, Stephenson Cancer Center, Oklahoma City, Oklahoma., Velazquez AI; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Ragavan M; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Lin JJ; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Piotrowska Z; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Wilgucki M; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Reuss J; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Luders H; Klinik für Pneumologie-Evangelische Lungenklinik Berlin Buch, Berlin, Germany., Grohe C; Klinik für Pneumologie-Evangelische Lungenklinik Berlin Buch, Berlin, Germany., Baena Espinar J; Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain., Feiner E; Perlmutter Cancer Center, New York University Langone Health, New York, New York., Punekar SR; Perlmutter Cancer Center, New York University Langone Health, New York, New York., Gupta S; Department of Hematology and Medical Oncology, Thoracic Medical Oncology Program, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Leal T; Department of Hematology and Medical Oncology, Thoracic Medical Oncology Program, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Kwiatkowski DJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Mak RH; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts., Adib E; Dana-Farber Cancer Institute, Boston, Massachusetts., Naqash AR; Oklahoma University, Stephenson Cancer Center, Oklahoma City, Oklahoma., Goldberg SB; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut. Electronic address: sarah.goldberg@yale.edu.

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Jun; Vol. 19 (6), pp. 928-940. Date of Electronic Publication: 2024 Jan 24.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/therapy , Acrylamides*/therapeutic use , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/pharmacology , Chemoradiotherapy*/methods , ErbB Receptors*/genetics , ErbB Receptors*/antagonists & inhibitors , Aniline Compounds*/therapeutic use, Humans ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Mutation ; Consolidation Chemotherapy/methods ; Indoles ; Pyrimidines

المؤلفون: Yu W; Department of Radiotherapy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075061, China., Ren C; Department of Pharmacy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075061, China., Zhang J; Department of Pharmacy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075061, China., Zhang J; Department of Pharmacy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075061, China., Wang J; Department of Pathology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075061, China., Zhang Z; Department of Pathology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075061, China., Song X; Department of Radiotherapy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075061, China. Electronic address: songxiaofl@hebeinu.edu.cn., Li T; School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China. Electronic address: tian@fmmu.edu.cn.

المصدر: Asian journal of surgery [Asian J Surg] 2024 Jun; Vol. 47 (6), pp. 2792-2793. Date of Electronic Publication: 2024 Feb 19.

نوع المنشور: Letter

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8900600 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0219-3108 (Electronic) Linking ISSN: 10159584 NLM ISO Abbreviation: Asian J Surg Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/surgery , Carcinoma, Non-Small-Cell Lung*/mortality , Lung Neoplasms*/surgery , Lung Neoplasms*/mortality , Postoperative Complications*/mortality, Humans ; Retrospective Studies ; Male ; Female ; Middle Aged ; Inflammation ; Survival Rate ; Aged ; Time Factors

المؤلفون: Wang XY; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China., Wang YJ; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China., Guo BW; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China., Hou ZL; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China., Zhang GX; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China., Han Z; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China., Liu Q; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China., Yao GD; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Electronic address: guodong_yao@126.com., Song SJ; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province, Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province, Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Electronic address: songsj99@163.com.

المصدر: Bioorganic chemistry [Bioorg Chem] 2024 Jun; Vol. 147, pp. 107367. Date of Electronic Publication: 2024 Apr 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 1303703 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2120 (Electronic) Linking ISSN: 00452068 NLM ISO Abbreviation: Bioorg Chem Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/metabolism , Cell Proliferation*/drug effects , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Autophagy-Related Protein-1 Homolog*/metabolism , Autophagy-Related Protein-1 Homolog*/antagonists & inhibitors , Drug Screening Assays, Antitumor* , Dose-Response Relationship, Drug*, Humans ; Structure-Activity Relationship ; Molecular Structure ; Diterpenes/pharmacology ; Diterpenes/chemistry ; Apoptosis/drug effects ; Animals ; Mice ; Antineoplastic Agents, Phytogenic/pharmacology ; Antineoplastic Agents, Phytogenic/chemistry ; Intracellular Signaling Peptides and Proteins/metabolism ; Intracellular Signaling Peptides and Proteins/antagonists & inhibitors ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/chemical synthesis

المؤلفون: Yin Z; Department of Pathology, Baoan Central Hospital of Shenzhen, Shenzhen, Guangdong, China., Zhang X; Department of Pathology, Baoan Central Hospital of Shenzhen, Shenzhen, Guangdong, China., Sun X; Master Degree Candidate, Affiliated Central Hospital of Shenyang Medical College, Shenyang, Liaoning, China., Huo Y; Department of Pathology, Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China., Ji N; Department of Docimasiology, Baoan Central Hospital of Shenzhen, China, Shenzhen, Guangdong, China., Chen K; Department of Laboratory Animal Science, China Medical University, Shenyang, Liaoning, China.

المصدر: American journal of physiology. Cell physiology [Am J Physiol Cell Physiol] 2024 Jun 01; Vol. 326 (6), pp. C1753-C1768. Date of Electronic Publication: 2024 Apr 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Physiological Society Country of Publication: United States NLM ID: 100901225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-1563 (Electronic) Linking ISSN: 03636143 NLM ISO Abbreviation: Am J Physiol Cell Physiol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/radiotherapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/metabolism , Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/radiotherapy , Lung Neoplasms*/genetics , Lung Neoplasms*/metabolism , Lung Neoplasms*/drug therapy , Ubiquitin Thiolesterase*/metabolism , Ubiquitin Thiolesterase*/genetics , Radiation Tolerance*/drug effects , Apoptosis*/drug effects, Humans ; Animals ; Mice ; Xenograft Model Antitumor Assays ; Mice, Nude ; Cyclooxygenase 2/metabolism ; Cyclooxygenase 2/genetics ; Cyclic AMP Response Element-Binding Protein/metabolism ; Cyclic AMP Response Element-Binding Protein/genetics ; A549 Cells ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell Survival/radiation effects ; Male ; Cell Proliferation/drug effects ; Gene Expression Regulation, Neoplastic ; Female ; Radiation-Sensitizing Agents/pharmacology

المؤلفون: Liang H; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China., Wang T; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China., Liu D; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China., Wang H; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China., Ba Z; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China., Xiao Y; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China., Liu Y; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China., Yuan J; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. jsyuantg@163.com.; Key Laboratory of Pulmonary Vascular Medicine, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. jsyuantg@163.com., Yang W; State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. wxyang2009@sina.com.; Key Laboratory of Pulmonary Vascular Medicine, National Center for Cardiovascular Diseases, FuWai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167 North Lishi Road, Xicheng District, Beijing, 100037, China. wxyang2009@sina.com.

المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Jun; Vol. 26 (6), pp. 1348-1356. Date of Electronic Publication: 2023 Dec 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Small Cell Lung Carcinoma*/therapy , Small Cell Lung Carcinoma*/mortality , Small Cell Lung Carcinoma*/pathology , Lung Neoplasms*/mortality , Lung Neoplasms*/therapy , Lung Neoplasms*/pathology , Cardiovascular Diseases*/mortality , Cardiovascular Diseases*/epidemiology , Chemoradiotherapy*, Humans ; Male ; Female ; Middle Aged ; Aged ; Prognosis ; Comorbidity ; Risk Factors ; Proportional Hazards Models ; Retrospective Studies ; China/epidemiology ; Pericardial Effusion/etiology ; Pericardial Effusion/epidemiology ; Pericardial Effusion/mortality ; Adult ; Survival Rate

المؤلفون: Kamigaichi A; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan., Tsutani Y; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan., Mimae T; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan., Miyata Y; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan., Adachi H; Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan., Shimada Y; Department of Surgery, Tokyo Medical University, Tokyo, Japan., Takeshima Y; Department of Pathology, Hiroshima University, Hiroshima, Japan., Ito H; Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan., Ikeda N; Department of Surgery, Tokyo Medical University, Tokyo, Japan., Okada M; Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.. Electronic address: morihito@hiroshima-u.ac.jp.

المصدر: Seminars in thoracic and cardiovascular surgery [Semin Thorac Cardiovasc Surg] 2024 Summer; Vol. 36 (2), pp. 273-281. Date of Electronic Publication: 2022 Dec 10.

نوع المنشور: Journal Article; Multicenter Study; Comparative Study

بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8917640 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-9488 (Electronic) Linking ISSN: 10430679 NLM ISO Abbreviation: Semin Thorac Cardiovasc Surg Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/diagnostic imaging , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/surgery , Lung Neoplasms*/pathology , Lung Neoplasms*/diagnostic imaging , Lung Neoplasms*/surgery , Tumor Burden* , Positron Emission Tomography Computed Tomography* , Neoplasm Staging* , Pneumonectomy* , Predictive Value of Tests* , Databases, Factual*, Humans ; Male ; Female ; Retrospective Studies ; Aged ; Middle Aged ; Reproducibility of Results ; Risk Factors ; Fluorodeoxyglucose F18

المؤلفون: Li Y; Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China., Wang N; Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China., Huang Y; Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China., He S; Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China; Molecular Medicine Diagnostic and Testing Center, Chongqing Medical University, Chongqing 400016, China., Bao M; Hunan key laboratory of the research and development of novel pharmaceutical preparations, Changsha Medical University, Changsha 410219, China; Academician Workstation, Changsha Medical University, Changsha 410219, China., Wen C; Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China. Electronic address: wenchunj@cqmu.edu.cn., Wu L; Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China. Electronic address: lxwu@cqmu.edu.cn.

المصدر: Cancer genetics [Cancer Genet] 2024 Jun; Vol. 284-285, pp. 34-42. Date of Electronic Publication: 2024 Apr 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101539150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2210-7762 (Print) NLM ISO Abbreviation: Cancer Genet Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Acrylamides*/therapeutic use , Acrylamides*/pharmacology , Aniline Compounds*/therapeutic use , Aniline Compounds*/pharmacology , Lung Neoplasms*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Drug Resistance, Neoplasm*/genetics , RNA, Circular*/genetics, Humans ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Gene Expression Regulation, Neoplastic/drug effects ; Cell Movement/drug effects ; Cell Movement/genetics ; Indoles ; Pyrimidines

المؤلفون: Favorito V; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Ricciotti I; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., De Giglio A; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Fabbri L; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Seminerio R; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Di Federico A; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Gariazzo E; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy., Costabile S; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy., Metro G; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.

المصدر: Expert opinion on emerging drugs [Expert Opin Emerg Drugs] 2024 Jun; Vol. 29 (2), pp. 139-154. Date of Electronic Publication: 2024 Apr 08.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101135662 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7623 (Electronic) Linking ISSN: 14728214 NLM ISO Abbreviation: Expert Opin Emerg Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/genetics , ErbB Receptors*/genetics , ErbB Receptors*/antagonists & inhibitors , Molecular Targeted Therapy* , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/administration & dosage , Mutation* , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/administration & dosage , Drug Resistance, Neoplasm*, Humans ; Drug Development ; Neoplasm Staging ; Animals

المؤلفون: Nadal E; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Avda Gran via, 199-203. L'Hospitalet, 08908, Barcelona, Spain; Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, OncoBell Program, IDIBELL, L'Hospitalet, Barcelona, Spain. Electronic address: esnadal@iconcologia.net., Rifi N; Pfizer, Inc., New York, New York, USA., Kane S; EVERSANA™, Burlington, Ontario, Canada., Mbacke S; EVERSANA™, Burlington, Ontario, Canada., Starkman L; EVERSANA™, Burlington, Ontario, Canada., Suero B; EVERSANA™, Burlington, Ontario, Canada., Le H; Pfizer, Inc., New York, New York, USA., Samjoo IA; EVERSANA™, Burlington, Ontario, Canada. Electronic address: imtiaz.samjoo@eversana.com.

المصدر: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Jun; Vol. 192, pp. 107816. Date of Electronic Publication: 2024 May 09.

نوع المنشور: Journal Article; Systematic Review; Meta-Analysis

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Crizotinib*/therapeutic use , Crizotinib*/adverse effects , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/mortality , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Proto-Oncogene Mas* , Proto-Oncogene Proteins*/genetics , Protein-Tyrosine Kinases*/genetics , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/adverse effects, Humans ; Oncogene Proteins, Fusion/genetics ; Treatment Outcome ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Gene Fusion